evipedia.ai
← Back

AHK-Cu for Health & Longevity

Evidence Review created on 10/02/2026 using AI4L / Opus 5.5

Also known as: Copper Tripeptide-3, AHK Copper Peptide, AHK-Copper, Alanyl-Histidyl-Lysine Copper, L-Alanyl-L-Histidyl-L-Lysine-Cu(II), Ala-His-Lys-Cu

Motivation

AHK-Cu (copper tripeptide-3) is a lab-made complex in which a short chain of three amino acids (alanine, histidine and lysine) holds a single copper ion. It is a close chemical cousin of a copper-carrying protein fragment that occurs naturally in human blood. The proposed idea is simple: the complex delivers copper to cells and nudges the signals that govern tissue growth and blood-vessel formation. Its appeal to longevity-minded adults lies in the hope of supporting two of the most visible tissues that change with age, the skin and the hair follicles.

Interest grew from laboratory work on human hair follicles kept alive outside the body, and from decades of research on its natural cousin in wound care and skin care. Today AHK-Cu appears in cosmetic scalp serums, in clinic-administered scalp treatments that combine several agents, and in online communities that discuss injecting it as an unapproved research chemical.

This review examines what is known about AHK-Cu itself, as distinct from its better-studied cousin: the quality of the human evidence, the likely mechanism, the safety questions raised by applying or injecting a copper complex, and how it is used in practice.

Benefits - Risks - Protocol - Conclusion

This section lists overview articles, reviews, and expert commentary that discuss AHK-Cu or the copper-tripeptide class it belongs to in depth.

No content on AHK-Cu by name was found from Rhonda Patrick, Peter Attia, Chris Kresser, Life Extension Magazine, or Lifespan.io, and Andrew Huberman’s coverage addresses only the related GHK-Cu; AHK-Cu remains a niche cosmetic and research-chemical compound that these sources have not reviewed.

Grokipedia

AHK tripeptide-3

An encyclopedic overview of AHK-Cu’s structure, synthesis, and reported biological activity, useful for chemistry background; its evidence summary rests on the same laboratory and animal data reviewed here.

Examine

No Examine article on AHK-Cu exists.

ConsumerLab

No ConsumerLab article on AHK-Cu exists.

Systematic Reviews

No systematic reviews or meta-analyses for AHK-Cu were found on PubMed as of October 1, 2026.

Neither the claimed hair and skin effects nor the principal risks (skin reactions, contaminated products) are represented by a systematic review or meta-analysis of AHK-Cu.

Mechanism of Action

AHK-Cu is L-alanyl-L-histidyl-L-lysine bound to copper(II). Like GHK-Cu, it belongs to the “Xxx-His” family of copper-binding peptides: copper is gripped by the free amino end, the next backbone nitrogen, and the histidine ring, forming a stable complex that resists the free-radical chemistry of loose copper (Gonzalez et al., 2018). Its sequence matches positions 2–4 of the copper-binding tip of serum albumin, the blood’s main carrier of loosely bound, exchangeable copper.

  • Follicle cell survival: in cultured human cells, AHK-Cu increased dermal papilla cell growth, raised the Bcl-2/Bax ratio (proteins that block versus promote cell death), and lowered cleaved caspase-3 and PARP (markers of cell death in progress) (Pyo et al., 2007).
  • Growth-factor shift (inferred from GHK-Cu): GHK-Cu raised VEGF (vascular endothelial growth factor, a blood-vessel growth signal) in skin fibroblasts (collagen-producing cells) (Pollard et al., 2005).
  • Copper supply: copper is a cofactor for lysyl oxidase (the enzyme that cross-links collagen and elastin).

Competing view: no receptor has been identified, effects may reflect copper delivery generally, and laboratory activity occurred at picomolar (trillionths of a mole per liter) concentrations far below those in commercial serums.

Pharmacology: half-life, selectivity and human tissue distribution have not been measured; skin penetration is limited without microneedling. Peptidases (protein-cutting enzymes) degrade it into amino acids; copper enters normal handling via ATP7B (a liver copper-export pump) and bile, without CYP (cytochrome P450 liver enzyme) involvement.

Historical Context & Evolution

AHK-Cu descends from GHK, a copper-binding tripeptide that Loren Pickart isolated from human plasma in 1973 while studying why blood from young people made aged liver tissue behave more youthfully (Pickart & Margolina, 2018). Its copper-bound form was then developed for wound care and cosmetics.

  • Commercial copper-peptide era (1980s–1990s): the company ProCyte developed copper-peptide wound and hair products. Its 1996 patent on hair growth by peptide-copper complexes (US5538945A) reported that AHK-Cu, applied to the skin or injected, stimulated hair growth in mice and preserved hair at injection sites in rats given chemotherapy, although its claims excluded AHK-Cu itself.
  • The 2007 follicle study: a Seoul National University team exposed human scalp follicles and dermal papilla cells to AHK-Cu. Follicles grew longer at picomolar to nanomolar concentrations, cell proliferation rose, and markers of programmed cell death fell (Pyo et al., 2007). The study was not replicated and no human trial followed.
  • Consumer adoption (recent years): AHK-Cu moved into scalp sprays and serums under the cosmetic name “copper tripeptide-3,” and later into online peptide-injection culture.

Scientific opinion has not turned against AHK-Cu; it was simply never tested further. What changed is context: recent reviews cite the 2007 study as the whole AHK-specific evidence base (Fan et al., 2026), and critiques of copper-peptide products now focus on undefined formulations rather than on negative results (Mateescu et al., 2026).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there are no controlled human trials of AHK-Cu, and the only compound-specific data come from human hair follicles kept alive outside the body and company animal experiments.

Medium 🟩 🟩

No benefit reaches Medium: no single human trial or consistent observational dataset has tested AHK-Cu, alone, on any clinical outcome.

Low 🟩

Scalp Hair Growth ⭕️ Not Central to Health & Longevity

AHK-Cu lengthened cultured human follicles and protected dermal papilla cells (Pyo et al., 2007). Human data are uncontrolled; in one series, seven men with androgenetic alopecia (inherited pattern hair loss) received minoxidil, dutasteride and unspecified copper peptides by scalp tattooing (Kuceki et al., 2025). This bears on appearance, not lifespan.

Magnitude: Median top-scalp regrowth was 26.5% after five sessions versus 10% in an earlier three-session protocol without copper peptides; the copper peptide’s own contribution cannot be separated.

Skin Repair and Skin Quality ⭕️ Not Central to Health & Longevity

AHK-Cu has no skin trial; evidence comes from its analog GHK-Cu. After carbon dioxide laser resurfacing, a small randomized trial found GHK-Cu skin care did not speed redness resolution or improve blinded wrinkle ratings, but patients rated skin quality higher (Miller et al., 2006). This bears on appearance, not lifespan.

Magnitude: In that 13-patient trial, objective redness, wrinkle and skin-quality scores did not differ from control, while self-rated skin quality favored GHK-Cu (P = .04, a result unlikely to be due to chance); the literature reports no effect size, and none exists for AHK-Cu.

Speculative 🟨

Systemic Tissue Repair and Anti-Inflammatory Effects

Injectable use rests on GHK-Cu animal and gene-expression work, including suppressed NF-κB (a master switch of inflammation) (Pickart & Margolina, 2018). No AHK-Cu systemic study exists; the basis is mechanistic only.

Protection Against Copper-Driven Oxidative Stress

Tightly bound copper cannot freely generate free radicals; the albumin-tip peptide DAHK (Asp-Ala-His-Lys) blocked copper-induced radical formation in vitro (Bar-Or et al., 2001). The basis for AHK-Cu is mechanistic only.

Benefit-Modifying Factors

  • Genetic drivers of hair loss: pattern hair loss depends on androgen-receptor sensitivity in scalp follicles. AHK-Cu does not act on androgen signalling, so strongly androgen-driven loss is less likely to respond to it alone.
  • Baseline copper and zinc status: people with low copper or ceruloplasmin (the main copper-carrying blood protein) might theoretically gain more from added copper; no study has tested whether baseline status changes response.
  • Sex: the main human hair series involved only men. Female pattern hair loss has a different pattern and hormonal profile, and no AHK-Cu data exist for women.
  • Type of hair loss: pattern hair loss and telogen effluvium (stress- or illness-related shedding of resting hairs) are plausible targets; alopecia areata (autoimmune patchy hair loss) and scarring alopecias (permanent follicle destruction) are unlikely to respond to a follicle-growth signal.
  • Age: older follicles are more miniaturized and older skin repairs more slowly, which may blunt visible response; no age-stratified data exist.
  • Delivery method: microneedling or tattoo-machine infusion greatly increases skin penetration; plain topical application of a water-soluble charged peptide reaches follicles poorly.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no controlled human trial of AHK-Cu has reported adverse events, so no risk rests on replicated human outcome data.

Medium 🟥 🟥

No risk reaches Medium: no single human trial or consistent observational dataset has recorded adverse events of AHK-Cu itself.

Low 🟥

Local Skin Irritation and Contact Allergy

Redness, itching or stinging at the application site is the most cited topical complaint, drawn from vendor and user reports rather than trials. True copper allergy is uncommon; pooled patch-test data rank copper as a very weak allergy trigger (Fage et al., 2014). Alcohol-based product bases may contribute.

Magnitude: A weighted average of 3.8% of people patch-tested for suspected metal-related symptoms reacted to copper; no irritation rate has been measured for AHK-Cu products.

Speculative 🟨

Contaminated, Mislabeled, or Underdosed Product

Unregulated injectable AHK-Cu has unverified sterility, identity and dose. Tested gray-market semaglutide vials all contained endotoxin (bacterial toxin) and had purity far below label (Ashraf et al., 2024). The basis is indirect product testing only.

Promotion of Existing Tumors

Tumors have heightened copper needs, and copper drives cell proliferation and blood-vessel growth (Ge et al., 2022). No data link AHK-Cu to cancer; the basis is mechanistic only.

Injection-Site and Immune Reactions

Injection can cause redness, swelling or lumps; an injected peptide may provoke an immune response, as the FDA (US Food and Drug Administration) noted for GHK-Cu. No AHK-Cu reports exist; the basis is mechanistic only.

Copper Accumulation With Impaired Copper Excretion

In Wilson disease (inherited failure of liver copper excretion) or severe cholestasis (blocked bile flow), extra copper could add to toxic load. Cosmetic amounts are tiny; the basis is mechanistic only.

Risk-Modifying Factors

  • ATP7B variants: people with two faulty ATP7B copies (Wilson disease) cannot excrete copper and face the greatest risk from added copper; carriers of a single variant are usually unaffected but may show mildly low ceruloplasmin.
  • Baseline copper markers: low ceruloplasmin (below 20 mg/dL) can signal undiagnosed Wilson disease; high serum copper suggests existing copper excess, where systemic AHK-Cu adds risk without expected benefit.
  • Sex and hormones: estrogen, oral contraceptives and pregnancy raise serum copper and ceruloplasmin; no sex difference in AHK-Cu side effects has been documented.
  • Skin barrier conditions: scalp psoriasis, seborrheic dermatitis (dandruff-type inflammation) or eczema increase absorption and irritation; open wounds or infection raise infection risk with non-sterile products.
  • Liver disease: cholestatic liver disease impairs biliary copper excretion and raises the stakes of injectable use.
  • Age: older adults have thinner, drier skin prone to irritation and a higher background cancer incidence, relevant to the theoretical tumor-growth concern.

Key Interactions & Contraindications

Prescription drugs

  • Copper chelators (drugs that bind and remove copper; penicillamine, trientine): Absolute contraindication for injectable AHK-Cu; added copper directly opposes Wilson disease therapy, risking copper re-accumulation and liver injury.
  • Topical retinoids (vitamin A-derived skin drugs; tretinoin, adapalene): Caution; combined use increases redness and peeling. Alternate-night or opposite-time-of-day application is the usual mitigation.
  • Topical minoxidil: Monitor; frequently combined for hair loss with no known chemical interaction, but alcohol and propylene glycol product bases add scalp irritation. Separating applications by several hours reduces irritation if it appears.
  • Estrogen-containing contraceptives or hormone therapy (ethinyl estradiol, estradiol): Monitor; they raise serum copper and ceruloplasmin, which complicates lab interpretation during systemic use. Noting hormone use when copper labs are read avoids misinterpretation.

Over-the-counter products

  • Exfoliating acids (glycolic, lactic, salicylic acid): Caution; acidic pH can strip copper from the peptide, reducing activity and increasing irritation. Application at a different time of day avoids this.
  • Vitamin C (L-ascorbic acid) serums: Caution; ascorbate reduces copper(II), which may destabilize the complex and generate free radicals. Separation by at least 12 hours avoids this.
  • EDTA-containing shampoos (ethylenediaminetetraacetic acid, a metal-binding preservative): Monitor; may pull copper from the complex, inactivating it and leaving free copper on the scalp. Applying AHK-Cu after rinsing, not together, avoids this.
  • Benzoyl peroxide: Caution; a strong oxidizer that can degrade the peptide and add irritation. Separate skin areas or application times avoid this.

Supplements

  • High-dose zinc (above 40 mg/day): Monitor; zinc lowers copper absorption, which matters only for systemic copper balance. Copper and zinc are typically checked together when both are used long term.
  • Copper supplements or multiminerals with copper: Monitor; additive copper when AHK-Cu is injected raises the risk of copper excess and liver injury. Keeping total copper below the tolerable upper intake level of 10 mg/day limits this.
  • GHK-Cu: Monitor; the same mechanism class, so stacking adds copper exposure and irritation without evidence of extra benefit. Using one copper peptide at a time avoids this.
  • Other hair-growth supplements (saw palmetto, pumpkin seed oil): Monitor; additive intent with no interaction data, but they make it impossible to attribute results to AHK-Cu. Starting one agent at a time keeps results attributable.

Other interventions

  • Microneedling or dermarolling: Caution; increases penetration and effect but also irritation and infection risk. Sterile solutions on freshly needled skin limit infection risk.
  • Laser resurfacing or chemical peels: Caution; applying copper peptides to freshly injured skin raises irritation risk. The procedure provider’s aftercare timing governs when application resumes.

Populations who should avoid AHK-Cu:

  • Wilson disease (ATP7B-confirmed, any stage) or unexplained ceruloplasmin below 20 mg/dL
  • Confirmed copper allergy (positive copper sulfate patch test)
  • Active melanoma or other skin cancer at or near the application site; any active cancer for injectable use
  • Cholestatic or advanced liver disease (Child-Pugh Class B or C, a liver-disease severity score) for injectable use
  • Pregnancy or breastfeeding (no safety data)
  • Open wounds or active infection at the application site

Risk Mitigation Strategies

  • Patch test before scalp use: applying the product to the inner forearm once daily for 3 days, and stopping if redness or itching develops, reduces the risk of widespread contact dermatitis.
  • Topical rather than injectable route: limiting use to cosmetic topical products avoids the sterility, endotoxin and dosing risks of unregulated injectable vials.
  • Verified identity and purity: a batch-specific certificate of analysis with HPLC (high-performance liquid chromatography) purity above 98% and mass-spectrometry identity guards against mislabeled GHK-Cu or degraded product.
  • Endotoxin and sterility testing for any injectable: vials with documented sterility and endotoxin within the official drug-standard limit of 5 endotoxin units per kilogram of body weight reduce fever, abscess and infection risk.
  • Wilson screening before systemic use: ceruloplasmin and serum copper are checked at baseline; ceruloplasmin below 20 mg/dL warrants evaluation before exposure, preventing copper-overload injury.
  • Formulation separation: applying AHK-Cu at a different time of day from vitamin C, exfoliating acids and benzoyl peroxide prevents complex breakdown and irritation.
  • Skin cancer check: a full-skin examination before starting and annually thereafter addresses the theoretical tumor-promotion concern.
  • Sterile microneedling technique: needle lengths of 0.5–1.5 mm, disinfected skin and sterile single-use devices reduce infection and scarring.

Therapeutic Protocol

  • Topical scalp serum (most common approach): cosmetic brands supply AHK-Cu serums or sprays at roughly 0.5–1% (some up to 8%), applied once or twice daily to a dry scalp for at least 3–6 months; concentrations are vendor-set, not trial-derived.
  • Microneedle-assisted infusion: dermatologist Carlos Wambier’s group delivered 1.2% copper peptides with minoxidil and dutasteride by scalp tattooing (2-mm needle exposure) monthly for five sessions (Kuceki et al., 2025); home microneedling is an untested adaptation.
  • Injectable use (unvalidated): online peptide communities and vendor dosing sites cite subcutaneous (under-the-skin) doses from about 50–200 mcg up to 1–2 mg daily for 4–8 weeks; no human study supports any injectable dose.
  • Conventional hair-loss therapy: dermatology practice relies on minoxidil and 5-alpha-reductase inhibitors (drugs that block conversion of testosterone to its stronger hair-miniaturizing form); AHK-Cu is used alongside or instead of these by different practitioners.
  • Time of day: no optimal time is established; evening scalp application allows longer contact and keeps it apart from morning vitamin C products.
  • Half-life: not measured in humans; small peptides are typically cleared from blood within minutes to hours by peptidases, while the skin reservoir after topical use is unknown.
  • Single versus split dosing: topical products are applied once or twice daily; no study compares split and single dosing.
  • Genetic factors: strongly androgen-driven pattern hair loss, often familial, may need an androgen-targeting agent alongside AHK-Cu; for ATP7B variant carriers, injectable use adds copper-overload risk.
  • Sex differences: no sex-specific dosing exists; combination protocols containing dutasteride carry a risk of genital birth defects in male fetuses for women who could become pregnant.
  • Age: older adults with thinner skin often start at the low end of concentration and daily frequency to limit irritation.
  • Baseline biomarkers: normal ceruloplasmin and serum copper are prerequisites for systemic use; standardized baseline scalp photographs make later response assessable.
  • Pre-existing conditions: active scalp dermatitis is typically treated first; alopecia areata and scarring alopecias are managed with disease-specific therapy rather than AHK-Cu.

Discontinuation & Cycling

  • Duration: AHK-Cu is used as an ongoing cosmetic regimen rather than a short course; any hair benefit is presumed to depend on continued use, as with other follicle-stimulating topicals.
  • Withdrawal effects: no withdrawal syndrome is known; regression of any gained hair over several months after stopping is plausible but has not been documented.
  • Tapering: not required; the product can be stopped abruptly, including immediately if irritation or allergy develops.
  • Cycling: no evidence supports cycling to maintain effect; some users pause for 4 weeks every 3–6 months, a practice with no documented rationale.

Sourcing and Quality

  • Cosmetic versus research grade: topical products are sold as cosmetics; injectable powders are labeled “research use only” and are not manufactured under pharmaceutical good manufacturing practice.
  • Identity confusion: many listings attach GHK-Cu’s registry number (CAS 49557-75-7, a Chemical Abstracts Service identifier) to AHK-Cu, so the label alone does not confirm which peptide is inside.
  • Certificate of analysis: a credible certificate reports batch-specific HPLC purity, mass-spectrometry identity, copper content, and heavy-metal testing from an independent laboratory, not only the supplier.
  • Appearance and stability: genuine powder is blue to violet and water-soluble; green or brown color or cloudiness suggests degradation, and acidic solutions (below about pH 5) release free copper.
  • Storage: powder is kept refrigerated and dry, away from light; reconstituted solutions are refrigerated and used within weeks.
  • Brands: AHK-Cu scalp products are sold by cosmetic brands such as Neurogan Health and DermaFactors; no brand has published independent potency testing, and no pharmacy-grade compounded AHK-Cu product is known.

Practical Considerations

  • Time to effect: hair growth cycles are slow; visible change requires at least 3–6 months, and the only human series assessed outcomes after 5 months.
  • Common pitfalls: confusing AHK-Cu with GHK-Cu, attributing results from multi-ingredient products to AHK-Cu, mixing it with acids or vitamin C, stopping before 3 months, and injecting untested gray-market vials.
  • Regulatory status: AHK-Cu is a cosmetic ingredient, not an FDA-approved (US Food and Drug Administration) drug; injectable forms are unregulated. The FDA listed injectable GHK-Cu as a compounding safety risk in 2023, then delisted it in 2026 after the nomination was withdrawn.
  • Cost and payers: topical products are inexpensive; insurers do not cover cosmetic hair treatment, so payer incentives do not shape this evidence base, while commercial incentives sit with product sellers.

Interaction with Foundational Habits

  • Sleep: no direct interaction; AHK-Cu has no known effect on sleep. Evening application fits naturally into a bedtime routine, and poor sleep can independently worsen shedding, which may confound assessment.
  • Nutrition: indirect; hair growth also depends on adequate protein, iron (ferritin), zinc and copper. Diets very high in zinc supplements lower copper absorption; iron or protein deficiency limits any follicle-stimulating effect.
  • Exercise: no direct interaction or effect on muscle growth; heavy sweating can dilute a freshly applied scalp product, so application after the post-workout shower preserves contact time.
  • Stress management: indirect; chronic stress triggers telogen effluvium, which AHK-Cu does not address at its cause. Stress-driven shedding can mask or mimic treatment response, making stress control part of a fair assessment.

Monitoring Protocol & Defining Success

Baseline testing: Before starting any systemic (injectable) use, serum copper, ceruloplasmin, plasma zinc and liver enzymes establish copper status and screen for undiagnosed Wilson disease or liver disease. For topical scalp use, laboratory testing is optional, but standardized baseline scalp photographs under fixed lighting, and ideally trichoscopy (magnified scalp imaging that counts hairs), make later response measurable.

Ongoing monitoring: For topical use, photographs are repeated at 3 and 6 months, then every 6 months. For injectable use, copper, ceruloplasmin and liver enzymes are rechecked at 4–8 weeks and then every 3–6 months while use continues. Any persistent irritation, rash, or unexplained fatigue prompts stopping and retesting.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum copper 80–120 µg/dL Detects copper excess or deficiency Conventional range about 70–140 µg/dL; higher with estrogen or pregnancy; morning, non-fasting acceptable
Ceruloplasmin 25–35 mg/dL Screens for Wilson disease; reflects copper status Conventional range about 20–35 mg/dL; below 20 mg/dL warrants evaluation; pair with serum copper
Plasma zinc 90–110 µg/dL Zinc and copper compete Conventional range about 60–120 µg/dL; fasting morning sample; copper-to-zinc ratio near 1.0 is the functional target
ALT Below 25 U/L Early sign of liver stress from copper or contaminants ALT = alanine aminotransferase, a liver enzyme; conventional upper limit about 40–55 U/L; pair with AST (aspartate aminotransferase, another liver enzyme)
Hair density by trichoscopy No established target; track change from own baseline Objective measure of benefit Same scalp site, lighting and magnification each time; assess at 3 and 6 months

Qualitative markers:

  • Visible scalp coverage in standardized photographs
  • Hair shedding during washing and brushing
  • Hair shaft thickness and texture
  • Scalp comfort (itching, redness, flaking)
  • Skin texture and firmness where applied to the face

Emerging Research

  • No registered AHK-Cu trial: a ClinicalTrials.gov search on October 1, 2026 found no trial of AHK-Cu (no NCT ID exists); the compound’s human evidence therefore remains limited to uncontrolled mixed-agent reports.
  • Copper-peptide wound trial: NCT07437586, a Phase 2 randomized trial giving each of 60 healthy adults two small wounds, one treated with topical GHK-Cu gel and one with a matching inactive gel, measures time to complete skin closure; it is recruiting and would inform the copper-tripeptide class, not AHK-Cu directly.
  • Microneedle delivery agenda: a systematic review of GHK-Cu, not AHK-Cu, found strong laboratory and animal data but no adequately powered human microneedle trial, and proposed trials in pattern hair loss and photoaging (sun-induced skin aging) (Najafi et al., 2026).
  • Formulation critique that could weaken the case: an evidence-mapping review argues copper-peptide products rarely define which copper species is active, and that clinical evidence is sparse and partly negative (Mateescu et al., 2026).
  • Copper and cancer biology: research on copper-dependent cell proliferation (Ge et al., 2022) could reveal whether pro-growth copper complexes carry a tumor-promotion signal, which would weaken the case for systemic use.
  • Hair-peptide field: a 2026 review of short peptides for hair loss flags unjustified dose selection and in-vitro-only safety testing, including for AHK-Cu (Fan et al., 2026); dose-finding work could strengthen or weaken current serum strengths.

Conclusion

AHK-Cu is a lab-made copper complex, a close relative of a natural copper-carrying protein fragment in human blood, marketed mainly for thicker scalp hair and firmer skin, and increasingly injected by people seeking broader repair effects. For health-focused adults who are willing to experiment, the central fact is how little of the evidence concerns AHK-Cu itself. Its direct support comes from a single laboratory study on human hair follicles kept alive outside the body, plus company experiments in animals. The closest human hair data come from a small group of clinic patients, with no comparison group, who received copper peptides together with established hair-loss drugs, so any contribution of the copper complex cannot be isolated. Skin claims are borrowed from its better-studied cousin, whose own results in the few studies with a comparison group were modest and mixed.

The main risks for topical use appear mild: skin irritation and, rarely, copper allergy. The more serious concerns attach to injection, where unregulated products may be impure, mislabeled, or contaminated, and where theoretical questions about copper, blood-vessel growth, and existing cancers remain unanswered. People with inherited copper-storage disease face a specific hazard.

Much of the available information about AHK-Cu comes from sellers of copper-peptide products, and a leading body of copper-peptide research comes from scientists whose company sells such products. Overall, the evidence base is thin and early, and neither its promise nor its safety for long-term or injected use has been established.

Top - Benefits - Risks - Protocol